The Food and Drug Administration (FDA) has finished its review of recent data and found no association between tiotropium (Spiriva HandiHaler) and an increased risk of stroke, MI, or death from a cardiovascular cause. Early in 2008, the FDA received several reports of a possible small increase in cardiovascular risk among patients taking tiotropium. Since then, the agency has reviewed data from Understanding the Potential Long-Term Impacts on Function with Tiotropium (UPLIFT), a 4-year trial involving nearly 6,000 patients with COPD.
   Patients in this trial showed no significant increase in the risk of stroke, MI, or cardiovascular death. FDA officials are suggesting that health care professionals continue to prescribe the Spiriva HandiHaler according to the drug label.
   Tiotropium is a long-acting anticholinergic bronchodilator used to treat COPD.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our Disclaimer .

© Copyright 2010 by Lippincott Williams & Wilkins